Search

Displaying results 3501 - 3510 of 10000 in total
  1. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada. … Dehydrocholic acid is a synthetic bile acid that was prepared from the oxidation of cholic acid with chromic acid [A33022]. It has been used for stimulation of biliary lipid secretion.

  2. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment … The drug is composed of an IL-6–binding trimer and a IgG-binding domain.

  3. Drug

    Dalbavancin

    go.drugbank.com/drugs/DB06219
    ApprovedInvestigational

    Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. … Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible

    Products: Dalbavancin Accord 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Dalbavancin ratiopharm 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
  4. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910] … [A261165] However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns.

  5. Drug

    Dorzagliatin

    go.drugbank.com/drugs/DB15123
    Investigational

    Dorzagliatin is under investigation in clinical trial NCT03173391 (Long-term Efficacy and Safety of HMS5552 in T2DM).

    Categories: Drugs Used in Diabetes
  6. Drug

    Metenkefalin

    go.drugbank.com/drugs/DB12668
    Investigational

    Metenkefalin is an endogenous opioid and beta-endorphin.[A203225] It has been shown to reduce chromosomal abberations in patients with multiple sclerosis. … [A203210] Metenkefalin, along with [tridecactide], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]

  7. Drug

    Thiabendazole

    go.drugbank.com/drugs/DB00730
    ApprovedVet approvedWithdrawn

    2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential.

  8. Drug

    Agmatine

    go.drugbank.com/drugs/DB08838
    Experimental

    As an investigational drug, it is being studied in a non-blinded prospective case study in the United States looking at patients who have been diagnosed with small fiber peripheral neuropathy between the … It is formed when arginine is decarboxylated by the enzyme arginine decarboxylase and is found naturally in ragweed pollen, ergot fungi, octopus muscle, herring sperm, sponges, and the mammalian brain.

    Synonyms: N-(4-aminobutyl)guanidine
  9. Drug

    Hexylcaine

    go.drugbank.com/drugs/DB00473
    ApprovedWithdrawn

    Hexylcaine has been discontinued in the US market. … Hexylcaine hydrochloride is also known as cyclaine and osmocaine. It is a short acting local anesthetic that acts through inhibition of sodium channels.

  10. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    Zongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). … [L53873,A274363] It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pathways while sparing wild-type epidermal growth factor receptor (EGFR), which